Advertisement

Topics

Latest Biological Therapy NewsRSS

12:46 EDT 27th April 2017 | BioPortfolio

Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels of Immunogenicity

-100% of subjects in 100 µg intramuscular (IM) cohort achieved HAI titers that are accepted correlate of seroprotection against seasonal flu- -mRNA-1440 safe and well tolerated; tolerability consistent with approved vaccines- -Data published in the journal Molecular Therapy; First human proof-of-concept data from Moderna’s novel...

Genovis AB Initiates Sales of GlyCLICK™

Today Genovis is launching GlyCLICK, a product for specific labeling of antibodies for purposes such as development of biopharmaceuticals. GlyCLICK is the first of a series of products based on a technology platform in which Genovis’ unique enzyme GlycINATOR® is combined with SiteClick™ technology from Life Technologies. GlyCLICK is a new technolo...

SRI International Awarded $4.7 Million in Agreements to Manufacture and Test Vaccine Against Venezuelan Equine Encephalitis

MENLO PARK, Calif., April 27, 2017 /PRNewswire/ -- SRI International has been awarded two agreements worth $4.7 million to manufacture and conduct clinical testing on a potential new vaccine against Venezuelan equine encephalitis (VEE), a serious viral infection for which there is currently no commercially available vaccine. The VEE virus (VEEV) is a type of alphavirus that typicall...

Advaxis Recognized as One of New Jersey’s “Best Places to Work 2017”

Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, was named to NJBIZ’s 2017 Best Places to Work in New Jersey list, as comp

Chromatography Resin Market Worth 2.46 Billion USD by 2021

PUNE, India, April 27, 2017 /PRNewswire/ -- The report "Chromatography Resin Market by Type (Natural, Synthetic, Inorganic media), Technique (Ion Exchange, Affinity, Hydrophobic Interaction, Size Exclusion, Multi-Modal), Application (Pharmaceutical & Biotechnology, Food & Beverage) - Global Forecast to 2021", Published by MarketsandMarkets, the market is projected to grow fr...

Potential New Mitochondrial Target for Heart Disease

The fundamental basics of ion exchangers that reside within the mitochondria—especially for cardiac cells—has been a foundational part of the biological sciences for decades. However, the specific molecular mechanisms involved in these transport channels has remained more enigmatic. Yet now, new research led by investigators at the Lewis Katz School of Medicine at Temple University (LKSOM) que...

Agenus to Report First Quarter 2017 Financial Results on May 4, 2017; Conference Call to Follow

LEXINGTON, Mass., April 27, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its first quarter 2017 financial results before the market opens on Thursday, May 4, 2017. Agenus executives will host a conference call at 11:00 a.m. ET the same day. To access the live call, dial 1...

Heska To Present at Four Upcoming Conferences

LOVELAND, Colo., April 27, 2017 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, will be presenting at the following upcoming conferences: May 3-4, 2017 - Deutsche Bank 42nd Annual Healthcare Conference at the InterContinental Boston Hotel, Boston, Mass. Kevin Wilson, Heska's Presi...

Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio

TOKYO and PARSIPPANY, N.J. and MUNICH, April 27, 2017 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced it is making an initial 15 billion yen investment to optimize and enhance its manufacturing capabilities to support its growing antibody drug conjugate (ADC) pipeline. "This strategic investment will bolster our leadership and expertise in ADC ...

KaloBios Pharmaceuticals Inc KBIO Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 20032017] Prices from USD $250

SummaryKaloBios Pharmaceuticals Inc KaloBios is a development stage biopharmaceutical company that develops medicines for neglected and rare diseases. The company offers benznidazole, a nitroimidazole derivative used for the treatment of Chagas disease, a parasitic infection caused due to protozoan organism called Trypanosoma cruzi. IfabotuzumabantiEphA3 and LenzilumabantiGMCSF, recombinant monocl...

Cancer Immunotherapy Market by Cancer Types, Therapies, End Users, Growth Trends and Forecast to 2021, Upcoming Research by iHealthcareAnalyst, Inc.

Maryland Heights, MO, April 27, 2017 --(PR.com)-- Cancer immunotherapy is the use of the immune system to treat cancer. It uses substances either made by the body or in a laboratory to improve or restore immune system function. There are several types of cancer immunotherapies, including monoclonal antibodies, non-specific immunotherapies, oncolytic virus therapy, T-cell therapy, and cancer vacci...

Amazentis SA Announces Successful Phase IA/IB Study Results In Healthy Elderly Subjects With The Food Metabolite Urolithin A

Oral presentation at the International Conference on Frailty and Sarcopenia Research in Barcelona to report the successful achievement of Phase 1 studys primary and secondary objectives Clinical data confirm biological activity of Urolithin A on human skeletal muscle mitochondria

Key Capital Corporation Announces Groundbreaking Liver Cancer Immunotherapy Results

SCOTTSDALE, AZ -- (Marketwired) -- 04/27/17 -- KEY CAPITAL CORPORATION (OTC PINK: KCPC) advises that in an open-label Phase II study of Hepko-V5 oral immunotherapeutic vaccine conducted in 75 patients with late stage hepatocellular carcinoma (HCC), an unprecedented 90% of patients were alive after a median 12 months of follow up, as reported in open access Journal of Hepatocellular Carcinoma (ht...

Zoetis Receives European Commission Marketing Authorization for Cytopoint® (lokivetmab)

The first monoclonal antibody authorized for veterinary use in the European Union A single injection of Cytopoint treats the clinical signs of atopic dermatitis in dogs, including itch and inflammation, for up to one month Targets and neutralizes canine interleukin-31 (cIL-31), a key cytokine involved i...

MedImmune LLC Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 20032017] Prices from USD $250

SummaryMedImmune LLC MedImmune is a biotechnology company operating as the global biologics subsidiary of AstraZeneca. It focuses on the research, development, manufacture and marketing of small molecules and biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibodies and other nextgeneration molecules targeting various diseases. Medimmune...

SAB Biotherapeutics Strengthens Board of Directors with Appointment of Biotech Veteran

Taps former international life science executive Thorkil Kastberg Christensen SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, today announced that Thorkil Kastberg Christensen has joined their Board of Directors. SAB, which was founded in 2014, develops human

Physicians’ Education Resource® Announces Collaborative Partnership with Spanish Lung Cancer Group for 1st Annual European Symposium on Lung Cancers™

Physicians’ Education Resource® announces a collaborative partnership with the Spanish Lung Cancer Group (GECP) for PER®’s 1st Annual European Symposium on Lung Cancers™. The symposium will be held in Barcelona, Spain, on July 7-8. In making the announcement, Phil Talamo, president of PER®, said: “It brings us great honor to work with s...

transOMIC technologies Launches transEDIT-dual CRISPR Combinatorial Gene Knockout Kits

HUNTSVILLE, Ala., April 26, 2017 /PRNewswire/ -- The simultaneous knockout of two genes can help identify functional relationships between genes, which can lead to a better understanding of biological systems and can have direct implications for cancer therapeutic development as well as other therapeutic advancements. The transEDIT-dual CRISPR arrayed library targets over 19,000 genes in the ...

Arsanis Completes $45.5 Million Series D Financing

Company set to advance pipeline of monoclonal antibodies for serious infectious diseases, including lead Phase 2 program ASN100 for the prevention of Staphylococcus aureus pneumonia in high-risk ICU patients Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection ...

The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran

— Pivotal trials will enroll approximately 1,500 subjects randomized to inclisiran versus approximately 1,500 subjects randomized to placebo, with a primary endpoint of LDL-C and an 18-month study period — — NDA submission anticipated at or around the end of 2019 — The Medicines Company (NASDAQ:MDCO) and Alnylam Pharmaceuticals, Inc. (...

Immunomic Vice President to Speak at Bio+Tech Conference 2017

Panel Will Discuss Transforming Ideas into Drugs That Can Potentially Treat Human Disease Tomorrow, Immunomic Therapeutics, Inc. (ITI) Senior Vice President of Research and Development Teri Heiland, Ph.D., will participate in a panel discussion on cell therapy for oncology research and the present turning point in cancer vaccines. Dr. Heiland will disc...

Morphotek To Present Its Proprietary RESPECT™ Antibody Drug Conjugate (ADC) Technology At The Upcoming 13th Annual PEGS Summit In Boston

EXTON, Pa., April 26, 2017 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it will present its REsidue-SPEcific Conjugation Technology (RESPECT™) at the 13th Annual PEGS Summit being held May 1-5 at the Seaport World Trade Center in Boston, MA.  The presentation will take place on Thursday, May 4 at 9:35 a.m. ET during the ADCs I: New Targets, Payloa...

Fast-Tracking Our Response to Pandemics

SOURCE: GSK DESCRIPTION:In the wake of global pandemics such as Ebola and Zika, there is consensus that the world needs to be better prepared. Finding better ways to prepare The threat of a new epidemic is not hypothetical. Beyond recent outbreaks, epidemics, and pandemics, the World Health Organization (WHO) lists 70 diseases with outbreak potential. With increased air travel for business and to...

AdAlta Quarterly Results and Cash Flow Statement

Highlights Successful fibrosis investor briefing in Melbourne Extension of our collaboration agreement with The Alfred Hospital Positive broker reports published on AdAlta by Patersons Securities, NDF Research and independent newsletter BioShares Constructive institutional investor and pharmaceutical partner engagement during the JP Morgan healthcare week in January, including a...

BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD). Kiadis‘ MAA with the EMA doesn’t come as a surprise. After the EMA recently accepted the Biotech’s Pediatric ... This awesome article BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy appeared first on Labiotech.eu. ...

Quick Search
Advertisement
 

review and buy Biological Therapy market research data and corporate reports here